Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBIBP-CorV vaccine for COVID-19 prevention in Africa (ECOVA-01)
NCT04984408Phase 3Unknown
- Sponsor
- International Vaccine Institute
- Start
- Oct 2021
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of BBIBP-CorV in coronavirus disease 2019 (COVID-19), sponsored by International Vaccine Institute. Primary endpoint: Protection against any COVID-19 disease at 2 years. Status: unknown.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04984408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984408.